BCR and chronic myelogenous leukemia, BCR-ABL1 positive: These results, in addition to the results from ASCEMBL that showed superior efficacy with asciminib compared with bosutinib at weeks 24 (month ≈ 6) and 96 (year ≈ 2), support asciminib as a therapy of choice for patients with CML-CP after ≥ 2 TKIs without BCR::ABL1T315I [15, 25].